Previous studies have associated FABP1 with nonalcoholic fatty liver disease and nephropathy in patients with T2D (83, 84), effectively underscoring its potential as a biomarker for metabolic dysfunction. The gene discussed is FABP1; the disease is metabolic dysfunction-associated steatotic liver disease.